pharmaceuticals

Entrepreneur and NBA team owner Mark Cuban has invested in and started businesses for years, but only one of those companies features his name. Recent commentary from Cuban shows how passionate he is about transforming the U.S. healthcare system. What Happened: Cuban launched the Mark Cuban Cost...

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus. While cash flow can come...

Key Takeaways: Alibaba Health delivered robust annual earnings, with revenue jumping 30% to 26.76 billion yuan But its medical services division still accounts for just 3.5% of overall revenue By Molly Wen The Covid pandemic galvanized the market for online healthcare in China, as users switched...

  Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) presented interim data from the ongoing Phase 2 GATEWAY study of ARO-ANG3, the company's investigational RNAi therapeutic designed to reduce expression of angiopoietin-like protein 3 (ANGPTL3), in patients with homozygous familial...

U.S. markets ended in the green on Friday with major indices gaining over 1% as investors and traders weighed in on the fall in U.S. Treasury yields. The Nasdaq Composite closed 1.97% higher while the S&P 500 rose 1.61%. The Dow Jones gained 1.17%. Meanwhile, the following are the five stocks...

The health care sector held up relatively well in a difficult year for stocks in 2022. On Wednesday, one analyst adjusted his coverage of two large cap pharmaceutical stocks heading into what could be a volatile 2023. The Analyst: Bank of America analyst Geoff Meacham upgraded Merck & Co Inc (...

As COVID-19 spreads through China, and the world’s second-largest economy is dealing with an overwhelming wave of new infections, shares of Chinese-based funeral and healthcare companies are going higher. The stock market play may not be over, as the country had not yet formally...

Major Wall Street indices closed in the red on Monday, in a reversal of last week’s rally driven by softer inflation data. On Sunday, Federal Reserve Governor Christopher Waller said markets should pay attention to the "endpoint" of rate increases, not the pace...

Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two years. But there is no question some big-name stocks performed better than others since the pandemic bottom. Johnson & Johnson's Bumpy Road: One company that has...

Moderna, Inc (NASDAQ: MRNA) spiked up almost 5% off Friday’s closing price at one point on Monday, before hitting a resistance level at the $179 level and running into a group of sellers.  The pharmaceutical company has been trading in a strong uptrend on the weekly chart since June 13,...

Johnson & Johnson (NYSE: JNJ) reported a 3% growth in net sales to $24.02 billion, surpassing the consensus estimate of $23.81 billion, and a 4.4% growth in adjusted earnings to $2.59 per share, beating Street expectations of $2.57 per share. Raymond James On Johnson & Johnson: Analyst...

SVB Securities, a division of SVB Financial Group (NASDAQ: SIVB), believes BioNTech SE – ADR (NASDAQ: BNTX) stock is trading below the most negative scenario for the COVID-19 vaccine market. The SVB Financial Analyst: Daina M. Graybosch upgraded the stock from Market Perform to...

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) creates new possibilities via medicine to cure diseases and improve people's lives, and over the past year, marked gains in investors’ portfolios. Since July 2021, Vertex Pharmaceuticals stock’s one-year return has outperformed...

Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced on Monday the discontinuation of the Vupanorsen clinical development program. Following this, there are no high-impact catalysts for the next 12 months that could unlock value, according to BofA Securities. The Ionis Pharmaceuticals Analyst:...

Following the recent pullback in Inovio Pharmaceuticals Inc.’s (NASDAQ: INO) shares, the stock valuation seems to have been stripped of most of the remaining COVID-19 value, according to BofA Securities. The Inovio Pharmaceuticals Analyst: Geoff Meacham upgraded the rating for Inovio...